DanielJosephFarrugiaMDPhD FACS

PubMed

• 42 citations
  Low Estrogen Receptor (ER)-Positive Breast Cancer and Neoadjuvant Systemic Chemotherapy: Is Response Similar to Typical ER-Positive or ER-Negative Disease?
  Alessandra Landmann, Daniel J. Farrugia, Li Zhu, Emilia J Diego, Ronald Johnson, Atilla Soran, David J. Dabbs, Beth Z. Clark, Shannon Puhalla, Rachel C. Jankowitz, Ada...> ;American Journal of Clinical Pathology. 2018 May 31
• 10 citations
  Is completion axillary lymph node dissection necessary in patients who are underrepresented in the ACOSOG Z0011 trial
  Brian J. Gebhardt, Joel Thomas, Zachary D. Horne, Colin E. Champ, Daniel J. Farrugia, Emilia J Diego, Gretchen M. Ahrendt, Sushil Beriwal> ;Advances in Radiation Oncology. 2018 Apr 24
• Prognostic Significance of Modified Residual Disease in Breast and Nodes (mRDBN) Algorithm After Neoadjuvant Chemotherapy for Breast Cancer.
  Beth Z. Clark, Daniel J. Farrugia, Alessandra Landmann, Emilia J Diego, David J. Dabbs, Shannon Puhalla, Rachel C. Jankowitz, Adam Brufsky, Gretchen M. Ahrendt, Prisci...> ;American Journal of Clinical Pathology. 2018 Mar 7
• 28 citations
  Magee Equation 3 predicts pathologic response to neoadjuvant systemic chemotherapy in estrogen receptor positive, HER2 negative/equivocal breast tumors
  Daniel J. Farrugia, Alessandra Landmann, Li Zhu, Emilia J Diego, Ronald Johnson, Marguerite Bonaventura, Atilla Soran, David J. Dabbs, Beth Z. Clark, Shannon Puhalla, ...> ;Modern Pathology. 2017 May 26
• 29 citations
  Improved Breast Cancer Care Quality Metrics After Implementation of a Standardized Tumor Board Documentation Template.
  Daniel J. Farrugia, Trevan D Fischer, Daniel Delitto, Lisa Spiguel, Christiana M. Shaw> ;Journal of Oncology Practice. 2015 Sep 1
• 50 citations
  Detection of Splicing Aberrations Caused by BRCA1 and BRCA2 Sequence Variants Encoding Missense Substitutions: Implications for Prediction of Pathogenicity
  Logan C. Walker, Phillip J. Whiley, Fergus J. Couch, Daniel J. Farrugia, Sue Healey, Diana Eccles, Feng Lin, Samantha Butler, Sheila A. Goff, Bryony A. Thompson, Sunil...> ;Human Mutation. 2010 Jun 1
• 20 citations
  Impaired p53 function leads to centrosome amplification, acquired ERα phenotypic heterogeneity and distant metastases in breast cancer MCF-7 xenografts
  A B D'Assoro, Robert Busby, I. D. Acu, Cosima Quatraro, M. M. Reinholz, Daniel J. Farrugia, Mark A. Schroeder, Cory Allen, Franca Stivala, Evanthia Galanis, Jeffrey L....> ;Oncogene. 2008 Jun 26
• 95 citations
  Functional assays for classification of BRCA2 variants of uncertain significance.
  Daniel J. Farrugia, Mukesh K. Agarwal, Vernon S. Pankratz, Amie M. Deffenbaugh, Dmitry Pruss, Cynthia Frye, Linda Wadum, Kiley J. Johnson, Jennifer Mentlick, Sean V. T...> ;Cancer Research. 2008 May 1
• 769 citations
  Secondary mutations as a mechanism of cisplatin resistance in BRCA2 -mutated cancers
  Wataru Sakai, Elizabeth M. Swisher, Beth Y. Karlan, Mukesh K. Agarwal, Jake Higgins, Cynthia Friedman, Emily Villegas, Céline Jacquemont, Daniel J. Farrugia, Fergus J....> ;Nature. 2008 Feb 28
• 55 citations
  Identification of BRCA1 missense substitutions that confer partial functional activity: potential moderate risk variants?
  Paul K. Lovelock, Amanda B. Spurdle, Myth T.S. Mok, Daniel J. Farrugia, Sunil R. Lakhani, Sue Healey, Stephen Arnold, Daniel D. Buchanan, kConFab Investigators, Fergus...> ;Breast Cancer Research. 2007 Nov 26
• 2 citations
  4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone from cigarette smoke stimulates colon cancer growth via beta-adrenoceptors.
  William K K Wu, Helen P S Wong, Shi W Luo, Kevin Chan, Fung Y Huang, Marco K C Hui, Emily K Y Lam, Vivian Y Shin, Yi N Ye, Ying H Yang, Chi H Cho> ;Cancer Research. 2005 Jun 15
• 5 citations
  Functional evaluation and cancer risk assessment of BRCA2 unclassified variants.
  Kangjian Wu, Shannon R Hinson, Akihiro Ohashi, Daniel Farrugia, Patricia Wendt, Sean V Tavtigian, Amie Deffenbaugh, David Goldgar, Fergus J Couch> ;Cancer Research. 2005 Jan 15
• 61 citations
  Genotoxic stress leads to centrosome amplification in breast cancer cell lines that have an inactive G1/S cell cycle checkpoint.
  Antonino B. D'Assoro, Robert Busby, Kelly M Suino, Emmanuella Delva, Gustavo J Almodovar-Mercado, Heidi Johnson, Christopher Folk, Daniel J. Farrugia, Vlad C. Vasile, ...> ;Oncogene. 2004 May 20
• 190 citations
  Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells.
  Makiko Taniai, A Grambihler, Hajime Higuchi, Nate Werneburg, Steve F. Bronk, Daniel J. Farrugia, Scott H. Kaufmann, Gregory J. Gores> ;Cancer Research. 2004 May 15
• Join now to see all

Lectures

• Why do Women Get Breast Cancer. 1 hour CME Lecture for Mammography Technologists 
  Centegra Gavers Breast Center, Crystal Lake, IL - 7/25/2018
• The Breast Cancer Answers You Need 
  Centegra Health Bridge, Crystal Lake, IL - 5/2018
• A Lymphedema Management Program for Tomorrow. 1 hour CME Lecture for Lymphedema Therapists 
  Centegra Sage Cancer Center, McHenry, IL - 5/2018
• Functional Classification of Variants of Uncertain Significance in Breast Cancer Predisposition Genes in an Era of Personalized Medicine: Opportunities and Challenges. 
  Sylvester Comprehensive Cancer Center, University of Miami - 4/2016
• Role of Postmastectomy Radiation Therapy in Breast Cancer 
  Society of Surgical Oncology Breast Fellowship Webinar - 12/2015
• Severe Radiation Changes after Lumpectomy and Radiation for Breast Cancer Requiring Mastectomy with Flap Coverage 
  Minnesota Surgical Society Fall Meeting - 10/2008
• BRCA2 and Centrosome Dynamics: Centrosome amplification and aberrant function in response to disruption of BRCA2 
  Mayo Clinic College of Medicine Symposium - 10/2006
• Join now to see all